Immunotherapy drug may delay cancer's return after surgery

NCT ID NCT02769520

Ongoing Disease control Sponsor: Assuntina G. Sacco, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the immunotherapy drug pembrolizumab can help people with head and neck cancer that has come back after initial treatment. After surgery to remove the recurrent tumor, participants receive pembrolizumab to see if it extends the time before the cancer returns again. The trial enrolled 27 adults and tracks how long they remain cancer-free and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Contacts and locations

Show contact details

Locations

UCSD Moores Cancer Center

La Jolla, California, 92093, United States
University of California Los Angeles

Torrance, California, 90505, United States
University of California San Francisco

San Francisco, California, 94115, United States